VANCOUVER, March 24 /PRNewswire-FirstCall/ -- Medsurge Medical (TSX-V: MSR) announced today the appointment of Mr. Richard Bear to the post of Chief Financial Officer, effective immediately.
Previous to joining Medsurge, Mr. Bear was the CFO of ID Biomedical. Mr. Bear played a major role in ID Biomedical's financings, acquisitions and the sale of the ID Biomedical to GlaxoSmithKline. Mr. Bear was also directly responsible for internal and external financial reporting, information technologies, treasury management, risk management and all related infrastructure and internal controls.
"The appointment of Richard Bear is a key hire, and demonstrates the Company's commitment to implementing its strategic plan by building a strong infrastructure that will aid us in successfully opening colorectal health clinics in the United States," said Tony Holler, Chairman of Medsurge.
About Medsurge:
Medsurge is a medical device technology company that has developed and is marketing through its CRH clinics, the first single use, patented, disposable, hemorrhoid banding system. Medsurge has begun to open Colorectal Health Clinics in the United States specializing in the treatment of Hemorrhoids, Fissures and Colon Cancer screening through 2 Tier FOBT. The first Clinic opened in September 2005 in Chicago. The Company has announced it will open CRH Clinics in Los Angeles and San Francisco in April. Medsurge is also developing a patented 2 Tier colon cancer diagnostic screen, Fecal Occult Blood Test (FOBT).
The information in this news release contains so-called "forward-looking" statements. These include statements regarding Medsurge's expectations, beliefs, intentions or strategies for the future, which may be indicated by words or phrases such as "anticipate", "expect", "intend", "plan", "will", "we believe", "Medsurge believes", "management believes" and similar language. All forward-looking statements are based on Medsurge's current expectations and are subject to risks and uncertainties and to assumptions made.
For further information, visit the Company's website at http://www.medsurgemedical.com/ or the SEDAR website at http://www.sedar.com/ or email us at
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
/Media Contact: Alicia Johnson, (310) 376-1920; Investor Contact: Dean Linden, (604) 633-1440/
